QPPV.COM KNOWLEDGE ASSESSMENT

Article 107i Urgent Union Procedures: Professional Knowledge Assessment

Test your understanding of the concepts covered by Article 107i Urgent Union Procedures: How Urgent Safety Action Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which inspection finding would most strongly indicate effective MAH governance of an Article 107i response?

The company retained only the final label text and deleted earlier analyses to avoid confusion The company can trace the original safety information through escalation, submission, regulatory outcome, implementation and ongoing monitoring The company relied on informal conversations instead of documented decisions because the procedure was urgent The company assigned all responsibilities to one individual without documented review

Question 2 of 10 What is the most effective way to manage questions from PRAC or its rapporteurs?

Answer only the parts of the question that support the MAH's position Maintain a controlled record of the question, evidence requested, owner, deadline, analysis, review and submitted response Ask each functional department to respond independently without central coordination Provide broad background information while leaving the specific question unresolved

Question 3 of 10 What does the possibility of immediate national protective action demonstrate about Article 107i?

A Union procedure prevents Member States from taking any interim action Member States may, where legally permitted and necessary to protect public health, take interim protective measures while the Union process continues National action automatically cancels the Article 107i procedure Only the MAH can authorise temporary suspension of a product nationally

Question 4 of 10 Which evidence package would best support a rapid but balanced PRAC assessment?

Only the most serious individual case reports, without exposure or benefit information A concise package covering the safety concern, exposure, supporting and limiting evidence, uncertainties, benefit-risk impact and possible regulatory measures A submission focused exclusively on defending the current product information A collection of all available documents without prioritisation or interpretation

Question 5 of 10 Which statement most accurately describes the overall purpose of the Article 107i mechanism?

To provide an accelerated commercial variation route for any important product change To allow coordinated Union-level assessment and protective action when an urgent pharmacovigilance concern meets the applicable legal conditions To transfer all national regulatory authority to PRAC To ensure that every urgent concern results in withdrawal of the product

Question 6 of 10 Which statement best describes PRAC's role in an Article 107i procedure?

PRAC leads the scientific pharmacovigilance assessment and adopts a recommendation within the applicable procedure PRAC acts as the final national licensing authority for every affected product PRAC initiates the procedure whenever an MAH reports a serious case PRAC implements all national product-information changes directly

Question 7 of 10 Which statement best captures the relationship between Article 107i and routine signal management?

Article 107i replaces signal detection and validation whenever a serious event is reported Routine signal management can identify and assess concerns, while Article 107i applies when the situation reaches the statutory threshold for urgent Union action Article 107i is a purely administrative process unrelated to pharmacovigilance assessment Every validated signal must proceed directly to Article 107i

Question 8 of 10 Why should an MAH distinguish an observed increase in adverse-event reports from an increase in true incidence?

Because reported cases are never relevant to regulatory decision-making Because the increase may reflect stimulated reporting, exposure changes, improved recognition or other explanations rather than a confirmed incidence increase Because only epidemiological studies may be submitted in an urgent procedure Because causal interpretation is not relevant to benefit-risk assessment

Question 9 of 10 Which downstream pathway is generally associated with nationally authorised medicines in an Article 107i procedure?

PRAC followed by CMDh and implementation through the relevant national authorisations, as applicable PRAC followed exclusively by the European Commission for every affected authorisation PRAC followed by the EMA Management Board acting as a national licensing authority PRAC followed by no further regulatory step because the recommendation is self-executing

Question 10 of 10 Which statement correctly distinguishes a PRAC recommendation from the final regulatory outcome?

A PRAC recommendation is always the final legally operative decision A PRAC recommendation is irrelevant once the procedure reaches CHMP or CMDh The recommendation is an important scientific conclusion, but the applicable downstream committee and legal implementation steps must still be identified The MAH may implement only the parts of the recommendation it considers scientifically justified

Article 107i Urgent Union Procedures: Professional Knowledge Assessment

Cookie Settings